Reuters logo
BRIEF-Aldeyra Therapeutics announces results from allergic conjunctivitis phase 2b clinical trial
2017年6月14日 / 上午11点23分 / 5 个月前

BRIEF-Aldeyra Therapeutics announces results from allergic conjunctivitis phase 2b clinical trial

June 14 (Reuters) - Aldeyra Therapeutics Inc

* Aldeyra Therapeutics announces results from allergic conjunctivitis phase 2b clinical trial and plans for phase 3 clinical testing

* One-point reduction versus control component of primary endpoint not met

* Plans to initiate phase 3 clinical testing with 0.5% ADX-102 following discussion with regulatory authorities in second half of this year

* 0.5% ADX-102 statistically superior to control and demonstrates late-phase anti-inflammatory activity differentiated from standard of care

* Both concentrations of adx-102 were generally well tolerated and there were no safety concerns observed during trial Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below